Bragar Eagle & Squire, PC is reminding investors of this class action lawsuit
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, reminds investors that class action
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for possible violations of
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for possible violations of
NEW YORK, Oct. 15, 2022 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for possible violations of
NEW YORK, Oct. 15, 2022 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for possible violations of
NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”)
NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”)
NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”)
The US Supreme Court refused of Novartis AG NVS Efforts to block the launch of generic versions of its multiple sclerosis drug Gilenya. Novartis
TORONTO, ON, Oct. 13, 2022 (GLOBE NEWSWIRE) — marble uses its flagship legal product, Medchart, to issue claimant authorization to law firms representing patients in
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, reminds investors that class action
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for possible violations of
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for possible violations of
NEW YORK, Oct. 15, 2022 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for possible violations of
NEW YORK, Oct. 15, 2022 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for possible violations of
NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”)
NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”)
NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”)
The US Supreme Court refused of Novartis AG NVS Efforts to block the launch of generic versions of its multiple sclerosis drug Gilenya. Novartis
TORONTO, ON, Oct. 13, 2022 (GLOBE NEWSWIRE) — marble uses its flagship legal product, Medchart, to issue claimant authorization to law firms representing patients in